Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
Clinical trial NCT03626545 · TERMINATED
Trial details
- NCT number
- NCT03626545
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-23
- Primary completion
- 2021-01-08
- Enrollment
- 245
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.